LBPO.ET01 · 实验与分子治疗 · Late-Breaking
Late-Breaking Research: Experimental and Molecular Therapeutics 1
- LB048 LB048 ARC-401——一种旨在克服癌症耐药和肿瘤异质性的靶向Nectin-4的三载荷first-in-class ADC，在大鼠和非人灵长类动物中显示出广泛的抗肿瘤活性和高耐受性 ARC-401 - a triple payload first-in-class ADC against Nectin-4 designed to overcome cancer resistance and tumor heterogeneity shows broad anti-tumor activity and high tolerability in rats and non-human primates Isabella Attinger-Toller, Philipp Probst, Romain Bertrand, Rachael Fay, Lia Kallenberger, Ramona Stark, Patrick Maurhofer, Emma Renard, Roger Santimaria, Bernd Schlereth, Dragan Grabulovski, Philipp Rene Spycher
-
-
- LB051 LB051 BCG048：一种靶向ITGB6和B7H3的新型双特异性双载荷ADC，在患者来源肿瘤异种移植模型中展现出强效疗效 BCG048, a novel bispecific dual-payload ADC targeting ITGB6 and B7H3, exhibited potent efficacy in patient-derived tumor xenograft models Benny Yang, Mengran Li, Haipeng Liu, Chengzhang Shang
- LB052 LB052 解锁完整的人类抗体库：具有完全人源化Lambda链和多样化遗传背景的新型人源化抗体小鼠模型 Unlocking the Full Human Antibody Repertoire: Novel Humanized Antibody Mouse Models with Fully Humanized Lambda Chains and Diversified Genetic Backgrounds Benny Yang, Lili Liu, Lijun Zhang, Yanshuang Li, Huizhen Zhao, Jiawei Yao
- LB053 LB053 一种新型CD16A纳米抗体平台克服Fc多态性局限，实现强效广谱的NK细胞衔接器疗法 A novel CD16A-nanobody platform overcomes Fc polymorphism limitations for potent and broad-spectrum NK cell engager therapeutics Tiong Sun Chia, Jia Liu, Shuming Lin, Wei Dai, Min Wu, Zhihai Wu
- LB054 LB054 HSC00189的临床前表征：一种靶向cadherin-6（CDH6）和叶酸受体α（FOLR1）用于治疗卵巢癌的新型双特异性ADC Preclinical characterization of HSC00189, a novel bispecific ADC targeting cadherin-6 (CDH6) and folate receptor alpha (FOLR1) for the treatment of ovarian cancer Hongbin Wang, Qingyuan Meng, He Li, Dong Yao, Tao Peng, Lei Chen, Yao Li, Zhijian Yao, Dengfeng Duan, Ruofeng Tang, Senlin Li, Hongjiao Dong, Pingming Tang, Min Xu, Yao Lu, Ju Wang, Pangke Yan
-
-
- LB057 LB057 将他汀类药物重定位用于局部晚期食管腺癌：整合scRNAseq、基于类器官的高通量药物筛选和患者层面的临床数据 Repurposing statins for locally advanced esophageal adenocarcinoma: Integrating scRNAseq, organoid based high throughput drug screening, and patient level clinical data Sanjima Pal, Luís Nuno Cruz Santos Castro, Megan Sperry, Qian Qiu, Shuyuan Wang, Mingyan (Iris) Kong, Nicholas Bertos, Betty Giannias, Cedric Julien, Wotan Zeng, Swneke Bailey, Donald E. Ingber, Lorenzo Ferri
- LB058 LB058 临床可操作的药物协同作用驱动转录组和代谢重编程，在三阴性乳腺癌中诱导铁死亡和凋亡 Clinically actionable drug synergy drives transcriptomic and metabolic reprogramming to induce ferroptosis and apoptosis in triple negative breast cancer Gokul M. Das, Chetan C. Oturkar, Junhyoung Park, Iqbal Aijaz, Christina Adams, Utpakl K. Mukhopadhyay, Melissa Dolan, Michalis Mastri, Alexan der J. Caradori, Manasori Oshi, Yali Zhang, Jianmin Zhang, Brent Boleslav, Donald Mager, Tagari Samanta, Seung Y. Yabn, Richa Mishra, Richa Mishra, John Ebos, Kazuaki Takabe, Kris Attwood, Beeny A. Kaipparettu
-
-
- LB062 LB062 DEM301：一种具有强效免疫调节活性、可用于难治性结直肠恶性肿瘤的新型双功能ADC DEM301, a novel bifunctional ADC with potent immunomodulatory activity for potential use in difficult to treat colorectal malignancies Agnieszka Denslow, Sarah E. Carden, Peter Sandy, Sandeep Kumar, Loise M. Francisco
-
-
-
- LB067 LB067 模块化多抗原T细胞杂交器（MATCH）平台实现跨血液系统和实体瘤的可调、强效免疫治疗 A modular Multi-Antigen T Cell Hybridizers (MATCH) platform enables tunable and potent immunotherapy across hematologic and solid tumors Shannuo Li, Yingduo Yang, Joseph Shami, Douglas Sborov, Paul Shami, Jiyuan Yang, Jindřich Kopeček
-
-
-
-
